Welcome to our dedicated page for Palvella Therapeutics news (Ticker: PVLA), a resource for investors and traders seeking the latest updates and insights on Palvella Therapeutics stock.
Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company developing investigational topical therapies for serious, rare skin diseases and vascular malformations that currently have no FDA-approved treatments. News about Palvella often centers on progress across its QTORIN™ platform, including clinical trial milestones, regulatory designations, and pipeline expansion.
The company’s lead candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is being studied in the Phase 3 SELVA trial for microcystic lymphatic malformations and in the Phase 2 TOIVA trial for cutaneous venous malformations, with additional development planned in clinically significant angiokeratomas. Updates on these programs include topline clinical results, details on trial design, and commentary from investigators and company leadership on efficacy and safety findings.
Palvella also reports news on its second product candidate, QTORIN™ pitavastatin, for disseminated superficial actinic porokeratosis, including announcements of its selection as a new QTORIN-derived therapy and plans for Phase 2 clinical evaluation. Regulatory and grant-related news, such as FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations and Orphan Products Grant funding, provide additional context on how regulators view the unmet need in the company’s target indications.
Investors and observers following PVLA news can expect coverage of quarterly financial results, corporate updates, leadership appointments in areas like medical affairs and innovation, and participation in healthcare conferences. This news stream helps track how Palvella advances its investigational programs, manages its development priorities, and positions its QTORIN™ platform within the rare dermatologic disease landscape, while consistently noting that its product candidates remain investigational and unapproved.
Niagen Bioscience (NAGE) has engaged Red Sky Partners and veteran dealmaker Martin Hendrix, Ph.D., to support advancement of its small-molecule investigational drug NB4168 and broader corporate growth and potential M&A initiatives.
Red Sky advisors Pauline Jen Ryan and Christopher Kiritsy bring decades of experience in biotechnology fundraising, drug development, commercialization, and strategic transactions. Ryan previously helped secure Kadcyla® and Sarclisa® partnerships at ImmunoGen and raise nearly $300 million through partnerships and public offerings. Kiritsy helped build Kos Pharmaceuticals into a fully integrated company that developed the Niaspan® franchise and was acquired by Abbott Laboratories for approximately $4 billion, and he serves on the board of Palvella Therapeutics (PVLA). Hendrix previously led M&A initiatives at Nestlé Health Science. NB4168 targets rare genetic diseases, with an initial focus on Ataxia Telangiectasia (A‑T), a severe childhood-onset condition with no FDA‑approved therapies.
Palvella Therapeutics (PVLA) has appointed pediatric dermatologist James R. Treat, M.D. as Chief Medical Officer, effective December 21, 2026.
Dr. Treat is a nationally recognized expert in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations, and angiokeratomas, and has nearly 20 years of clinical, research, and academic experience. He has been a longstanding collaborator with Palvella and a site investigator at Children’s Hospital of Philadelphia for Phase 3 SELVA and Phase 2 studies of QTORIN™ rapamycin in microcystic lymphatic malformations. As CMO, he will lead medical strategy across clinical development, medical affairs, and scientific engagement while Palvella advances QTORIN rapamycin and its rare disease pipeline.
Palvella Therapeutics (PVLA) will participate in two healthcare investor conferences in September 2026. CEO and Founder Wes Kaupinen will join a fireside chat at the Cantor Global Healthcare Conference 2026 on September 9, 2026, at 1:35 p.m. ET, and deliver a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 12:00 p.m. ET. Live webcasts and 90-day replays will be accessible via the Events & Presentations section of the company’s website.
Palvella Therapeutics (Nasdaq: PVLA) has completed the rolling submission of a New Drug Application to the FDA for QTORIN™ 3.9% rapamycin anhydrous gel to treat microcystic lymphatic malformations (microcystic LMs), a rare, debilitating genetic disease with no current FDA‑approved therapies.
The NDA, filed via the 505(b)(2) pathway, includes Phase 2 data and pivotal Phase 3 SELVA trial results, where all six efficacy endpoints met statistical significance (all p<0.001). At Week 24, 86% of participants ≥6 years were rated “Much Improved” or “Very Much Improved” on the primary mLM-IGA endpoint. QTORIN™ rapamycin was reported as well tolerated, with no drug-related serious adverse events and systemic rapamycin levels below 2 ng/mL in all participants.
According to Palvella, QTORIN™ rapamycin has FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations. Within 60 days, the FDA will decide on filing acceptance and potential Priority Review. The company is advancing U.S. launch readiness for a potential first-half 2027 launch, if approved.
Palvella Therapeutics (Nasdaq: PVLA) announced that Founder and CEO Wes Kaupinen will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 3:30 p.m. ET. A live webcast and 90-day replay will be accessible via the Events and Presentations section of Palvella's website.
Palvella Therapeutics (Nasdaq: PVLA) reported Q2 2026 results and a broad clinical and regulatory update. The company submitted the first module of its rolling NDA to the FDA for QTORIN™ rapamycin in microcystic lymphatic malformations, under Breakthrough Therapy and Fast Track designations, and remains on track to complete the NDA in the second half of 2026. Palvella is preparing for a planned standalone U.S. commercial launch in the first half of 2027, if approved. Additional milestones include planned Phase 3 initiation in cutaneous venous malformations in Q4 2026, ongoing Phase 2 LOTU trial in angiokeratomas, and a Phase 2 trial of QTORIN™ pitavastatin in DSAP expected to start in the second half of 2026. As of June 30, 2026, cash, cash equivalents and short-term investments totaled $250.6 million. Q2 2026 research and development expenses were $12.5 million and general and administrative expenses were $8.9 million, leading to a net loss of $21.9 million, or $1.52 per share.
Palvella Therapeutics (Nasdaq: PVLA) announced that its Chief Scientific Officer, Jeffrey Martini, Ph.D., has been selected to provide public comment at the FDA public workshop “Drug Repurposing: Considerations for Selection Criteria and Prioritization” on August 5, 2026, in Washington, D.C.
According to Palvella, Dr. Martini will address evidence frameworks and regulatory approaches for advancing repurposed therapies, particularly for serious, rare diseases with significant unmet medical needs. The hybrid meeting, convened by the Reagan-Udall Foundation in collaboration with FDA, will examine how to identify, prioritize, and efficiently advance repurposing candidates using existing safety profiles and real-world evidence.
Palvella Therapeutics (Nasdaq: PVLA) will report its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Management will host an investor conference call and webcast at 8:30 a.m. ET that day, with online and phone access plus a 90-day replay.
Palvella Therapeutics (Nasdaq: PVLA) appointed Matt Pauls, J.D., M.B.A., to its Board of Directors. Pauls brings over 25 years of biopharma experience advancing and commercializing therapies for serious and rare diseases.
His background includes CEO and Board roles at Savara, Strongbridge, Soleno, and senior commercial posts at Insmed, Shire, Bristol Myers Squibb, and Johnson & Johnson.
Palvella Therapeutics (Nasdaq: PVLA) submitted the first module of its rolling New Drug Application to the FDA for QTORIN™ 3.9% rapamycin gel to treat microcystic lymphatic malformations. Palvella targets completion of the NDA in 2H 2026 and a potential standalone US launch in 1H 2027, if approved.
QTORIN™ rapamycin is backed by a Phase 3 SELVA study with highly statistically significant results across all endpoints and favorable tolerability, and holds FDA Breakthrough Therapy, Orphan Drug, Fast Track designations plus an Orphan Products Development grant, addressing an estimated >30,000 US patients.